STOCK TITAN

Charles River Laboratories International, Inc. - CRL STOCK NEWS

Welcome to our dedicated page for Charles River Laboratories International news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.

Founded in 1947, Charles River Laboratories International, Inc. (symbol: CRL) is a global leader in providing essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions. The company's mission is to accelerate research and drug development efforts, significantly contributing to the healthcare industry.

Charles River operates through three main segments:

  • Research Models & Services: This segment is renowned for being the leading provider of laboratory animal models. Charles River breeds and supplies animals with specific genetic traits for preclinical studies worldwide, supporting the critical early stages of drug discovery.
  • Discovery & Safety Assessment: This segment offers a comprehensive range of services necessary for the early development of new drugs. From discovery services to safety assessments, Charles River helps clients navigate the complex process of taking a drug from concept to early-stage development.
  • Manufacturing Support: This includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services. These services are integral to ensuring the safe manufacture and quality control of new therapies.

The company's workforce is dedicated to providing clients with the expertise and services they need to improve and expedite the discovery and development of new therapies. Charles River's collaborative approach and commitment to excellence have established it as a trusted partner in the life sciences industry.

Charles River continues to innovate and expand its services, making significant strides in the fields of drug discovery, biotechnology, and pharmaceuticals. With a strong financial footing and strategic partnerships, the company is well-positioned to support the future of healthcare advancements globally.

Rhea-AI Summary
NGS assay demonstrates greater capability in detecting viral contaminants compared to in vivo tests
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories collaborates with Fondazione Telethon to produce HQ plasmid DNA for lentivirus production in ex vivo gene therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
CRL - Charles River Laboratories International, Inc. reports second-quarter revenue of $1.06 billion, with GAAP earnings per share of $1.89 and non-GAAP earnings per share of $2.69. The company updates its 2023 guidance, narrowing its revenue growth and non-GAAP earnings per share outlooks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
Rhea-AI Summary
Charles River Laboratories International, Inc. is expanding its contract vivarium space for the biopharmaceutical industry with the planned openings of Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia. The CRADL facilities will provide flexible vivarium space and on-demand in vivo study support services to meet the growing demand in these cities. The CRADL Vivarium Network now operates 32 vivaria in key biohubs worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2023 financial results on August 9th. A conference call has been scheduled for investors to discuss this information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. and the INADcure Foundation have announced a plasmid DNA manufacturing alliance to support Phase I/II clinical trials for Infantile Neuroaxonal Dystrophy (INAD). INAD is a rare neurodegenerative disease with no known treatment or cure, affecting over 150 children worldwide. Charles River will utilize its expertise in High Quality (HQ) plasmid DNA production to manufacture the leading candidate for clinical trials. The collaboration aims to accelerate research and drive drug discovery for this rare disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences

FAQ

What is the current stock price of Charles River Laboratories International (CRL)?

The current stock price of Charles River Laboratories International (CRL) is $195.77 as of November 22, 2024.

What is the market cap of Charles River Laboratories International (CRL)?

The market cap of Charles River Laboratories International (CRL) is approximately 10.6B.

What services does Charles River Laboratories provide?

Charles River provides research models, discovery and safety assessment services, and manufacturing support, including microbial solutions, biologics testing, and avian vaccine services.

When was Charles River Laboratories founded?

Charles River Laboratories was founded in 1947.

Who are Charles River Laboratories' primary clients?

The company's primary clients are pharmaceutical and biotechnology companies, government agencies, and leading academic institutions.

What is Charles River Laboratories' mission?

Charles River's mission is to accelerate research and drug development efforts globally.

What is included in the Research Models & Services segment?

This segment includes providing laboratory animal models with specific genetic traits for preclinical studies.

What does the Discovery & Safety Assessment segment offer?

This segment offers services for the early development of new drugs, including discovery services and safety assessments.

What are some of the services provided under Manufacturing Support?

Manufacturing Support includes microbial solutions for in vitro testing, biologics testing services, and avian vaccine services.

How does Charles River contribute to the healthcare industry?

Charles River helps expedite the discovery and development of new therapies, aiding in research and the safe manufacture of new drugs.

What makes Charles River Laboratories a trusted partner in the life sciences industry?

The company's commitment to excellence, innovative approach, and comprehensive service offerings make it a trusted partner.

What is the ticker symbol for Charles River Laboratories International, Inc.?

The ticker symbol for Charles River Laboratories International, Inc. is CRL.

Charles River Laboratories International, Inc.

NYSE:CRL

CRL Rankings

CRL Stock Data

10.63B
50.64M
0.92%
103.97%
3.62%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States of America
WILMINGTON